Vitamin D Status, Cardiovascular Risk Profile, and miRNA-21 Levels in Hypertensive Patients: Results of the HYPODD Study

The vitamin D and microRNA (miR) systems may play a role in the pathogenesis of cardiometabolic disorders, including hypertension. The HYPODD study was a double-blind placebo-controlled trial aiming to assess the effects of cholecalciferol treatment in patients with well-controlled hypertension and hypovitaminosis D (25OHD levels < 50 nmol/L). In addition to this clinical trial, we also evaluated the effects of cholecalciferol and calcitriol treatment on miR-21 expression in vivo and in vitro, respectively. Changes in the cardiovascular risk profiles were evaluated in HYPODD patients treated with cholecalciferol (C-cohort) or with placebo (P-cohort). The miR-21circulating levels were measured in four C-cohort patients and five P-cohort patients. In vitro, the miR-21 levels were measured in HEK-293 cells treated with calcitriol or with ethanol vehicle control. Cholecalciferol treatment increased 25OHD levels and reduced parathormone, total cholesterol, and low-density lipoprotein cholesterol levels in C-cohort patients, whereas no significant changes in these parameters were observed in P-cohort patients. The miR-21 circulating levels did not change in the C- or the P-cohort patients upon treatment. Calcitriol treatment did not affect miR-21 levels in HEK-293 cells. In conclusion, hypovitaminosis D correction ameliorated the cardiovascular risk profiles in hypertensive patients treated with cholecalciferol but did not influence the miR-21 expression.

[1]  G. De Luca,et al.  Low levels of vitamin D and coronary artery disease: Is it time for therapy? , 2022, Kardiologia polska.

[2]  Y. Gunes,et al.  Poorly controlled hypertension is associated with elevated serum uric acid to HDL-cholesterol ratio: a cross-sectional cohort study , 2022, Postgraduate medicine.

[3]  Wen Zhang,et al.  The effect of vitamin D on the lipid profile as a risk factor for coronary heart disease in postmenopausal women: a meta-analysis and systematic review of randomized controlled trials , 2022, Experimental Gerontology.

[4]  Kaijian Hou,et al.  Vitamin D and Lipid Profiles in Postmenopausal Women: A Meta-Analysis and Systematic Review of Randomized Controlled Trials , 2021, Frontiers in Molecular Biosciences.

[5]  C. Rowland,et al.  Association of changes in lipid levels with changes in vitamin D levels in a real-world setting , 2021, Scientific Reports.

[6]  E. Goodman,et al.  Vitamin D supplementation and cardiometabolic risk factors among diverse schoolchildren: a randomized clinical trial. , 2021, American Journal of Clinical Nutrition.

[7]  M. Golmohammadi,et al.  Vitamin D3 and erythropoietin protect against renal ischemia-reperfusion injury via heat shock protein 70 and microRNA-21 expression , 2020, Scientific Reports.

[8]  E. Cavalier,et al.  Cardiovascular risk in patients with primary hyperparathyroidism. , 2020, Current pharmaceutical design.

[9]  L. Buja,et al.  Prevention of heart failure with preserved ejection fraction (HFpEF): reexamining microRNA-21 inhibition in the era of oligonucleotide-based therapeutics. , 2020, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.

[10]  T. Arimoto,et al.  The association between microRNA-21 and hypertension-induced cardiac remodeling , 2020, PloS one.

[11]  Chih-Yang Hsu,et al.  The effects of correction of vitamin D deficiency on arterial stiffness: A systematic review and updated meta-analysis of randomized controlled trials , 2019, The Journal of Steroid Biochemistry and Molecular Biology.

[12]  R. Bouillon,et al.  Vitamin D and cardiovascular disorders , 2019, Osteoporosis International.

[13]  Shengbo Xu,et al.  Insight into miRNAs related with glucometabolic disorder. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[14]  K. Peris,et al.  Dietary compounds as potential modulators of microRNA expression in psoriasis , 2019, Therapeutic advances in chronic disease.

[15]  J. Ge,et al.  Evaluation of the performance of serum miRNAs as normalizers in microRNA studies focused on cardiovascular disease. , 2018, Journal of thoracic disease.

[16]  G. Aktas,et al.  Haemogram Parameters in Vitamin D Deficiency. , 2018, Journal of the College of Physicians and Surgeons--Pakistan : JCPSP.

[17]  G. Lip,et al.  2018 ESC/ESH Guidelines for the management of arterial hypertension. , 2018, European heart journal.

[18]  Yongxiang Wei,et al.  microRNA-21 and hypertension , 2018, Hypertension Research.

[19]  M. Nitti,et al.  microRNA-494 Favors HO-1 Expression in Neuroblastoma Cells Exposed to Oxidative Stress in a Bach1-Independent Way , 2018, Front. Oncol..

[20]  W. Zhou,et al.  MicroRNA‐21 down‐regulates inflammation and inhibits periodontitis , 2018, Molecular immunology.

[21]  V. Gudnason,et al.  Effects of vitamin D supplementation on markers for cardiovascular disease and type 2 diabetes: an individual participant data meta-analysis of randomized controlled trials. , 2018, The American journal of clinical nutrition.

[22]  M. Kopeć-Mędrek,et al.  Systemic sclerosis sine scleroderma. , 2017, Advances in clinical and experimental medicine : official organ Wroclaw Medical University.

[23]  P. Fasching,et al.  A nutraceutical approach (Armolipid Plus) to reduce total and LDL cholesterol in individuals with mild to moderate dyslipidemia: Review of the clinical evidence. , 2017, Atherosclerosis. Supplements.

[24]  P. López-Jaramillo,et al.  A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension , 2016, The Lancet.

[25]  A. Józkowicz,et al.  TGF-β1/Smads and miR-21 in Renal Fibrosis and Inflammation , 2016, Mediators of inflammation.

[26]  E. Yıldırım,et al.  OP-049 A Novel Marker for Asymptomatic Organ Damage in the Patients with Hypertension: MIR-21 , 2016 .

[27]  C. Morrison,et al.  Diet-derived 25-hydroxyvitamin D3 activates vitamin D receptor target gene expression and suppresses EGFR mutant non-small cell lung cancer growth in vitro and in vivo , 2015, Oncotarget.

[28]  P. Vardas,et al.  Hypertrophic and antihypertrophic microRNA levels in peripheral blood mononuclear cells and their relationship to left ventricular hypertrophy in patients with essential hypertension. , 2015, Journal of the American Society of Hypertension : JASH.

[29]  H. Uzun,et al.  Circulating miR-21 and eNOS in subclinical atherosclerosis in patients with hypertension , 2015, Clinical and experimental hypertension.

[30]  Martin Healy,et al.  An Association between MicroRNA-21 Expression and Vitamin D Deficiency in Coronary Artery Disease. , 2015, MicroRNA.

[31]  F. Gianfrancesco,et al.  Hypovitaminosis D and Organ Damage In Patients With Arterial Hypertension: A Multicenter Double Blind Randomised Controlled Trial of Cholecalciferol Supplementation (HYPODD) , 2015, High Blood Pressure & Cardiovascular Prevention.

[32]  Li Wang,et al.  Emerging role of microRNAs in lipid metabolism , 2015, Acta pharmaceutica Sinica. B.

[33]  P. Strazzullo,et al.  Vitamin D and Cardiometabolic Disorders , 2014, High Blood Pressure & Cardiovascular Prevention.

[34]  D. Trump,et al.  Vitamin D and miRNAs in cancer. , 2014, Current Gene Therapy.

[35]  P. Briss,et al.  Prevention of chronic disease in the 21st century: elimination of the leading preventable causes of premature death and disability in the USA , 2014, The Lancet.

[36]  M. Campbell.  Vitamin D and the RNA transcriptome: more than mRNA regulation , 2014, Front. Physiol..

[37]  P. Muntner,et al.  High Blood Pressure: The Leading Global Burden of Disease Risk Factor and the Need for Worldwide Prevention Programs , 2013, Current Hypertension Reports.

[38]  Jiuyong Li,et al.  Identifying miRNAs, targets and functions , 2012, Briefings Bioinform..

[39]  W. März,et al.  Vitamin D and cardiovascular disease: Update and outlook , 2012, Scandinavian journal of clinical and laboratory investigation. Supplementum.

[40]  M. Yılmaz,et al.  Relation of serum parathyroid hormone level to severity of heart failure. , 2012, The American journal of cardiology.

[41]  B. Kestenbaum,et al.  Vitamin D, Parathyroid Hormone, and Sudden Cardiac Death: Results From the Cardiovascular Health Study , 2011, Hypertension.

[42]  P. Strazzullo,et al.  Should vitamin D status be assessed in patients with congestive heart failure? , 2010, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[43]  R. Fillingim,et al.  What is controlled for in placebo-controlled trials? , 2005, Mayo Clinic proceedings.

[44]  T. Oppé,et al.  Vitamin D deficiency. , 1979, British medical journal.

[45]  Thomas Kahan,et al.  [2018 ESC/ESH Guidelines for the management of arterial hypertension]. , 2019, Kardiologia polska.

[46]  G. Aktas,et al.  Diabetic regulation of subjects with type 2 diabetes mellitus is associated with serum vitamin D levels. , 2019, Revista da Associacao Medica Brasileira.

[47]  J. Adams,et al.  Vitamin D and microRNAs in bone. , 2013, Critical reviews in eukaryotic gene expression.